224 related articles for article (PubMed ID: 34192946)
1. Immune-related myocarditis in two patients receiving camrelizumab therapy and document analysis.
Zhang C; Qin S; Zuo Z
J Oncol Pharm Pract; 2022 Sep; 28(6):1350-1356. PubMed ID: 34192946
[TBL] [Abstract][Full Text] [Related]
2. [Clinical features of immune checkpoint inhibitor-related myositis in patients with urological cancer].
Ying YC; Tang Q; Yang KW; Mi Y; Fan Y; Yu W; Song Y; He ZS; Zhou LQ; Li XS
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Aug; 54(4):644-651. PubMed ID: 35950386
[TBL] [Abstract][Full Text] [Related]
3. A retrospective study of immune checkpoint inhibitor-associated myocarditis in a single center in China.
Wang F; Sun X; Qin S; Hua H; Liu X; Yang L; Yang M
Chin Clin Oncol; 2020 Apr; 9(2):16. PubMed ID: 32279526
[TBL] [Abstract][Full Text] [Related]
4. Successful management of camrelizumab-induced immune-checkpoint-inhibitors-related myocarditis.
Long HD; Du YP; Wang LY; Liu GC; Liang SX; Zeng ZH; Lin YE
J Oncol Pharm Pract; 2024 Apr; 30(3):597-604. PubMed ID: 38043937
[TBL] [Abstract][Full Text] [Related]
5. Myocarditis related to immune checkpoint inhibitors treatment: two case reports and literature review.
Chen Y; Jia Y; Liu Q; Shen Y; Zhu H; Dong X; Huang J; Lu J; Yin Q
Ann Palliat Med; 2021 Jul; 10(7):8512-8517. PubMed ID: 34263614
[TBL] [Abstract][Full Text] [Related]
6. Case Report: Glucocorticoid Effect Observation in a Ureteral Urothelial Cancer Patient With ICI-Associated Myocarditis and Multiple Organ Injuries.
Hu X; Wei Y; Shuai X
Front Immunol; 2021; 12():799077. PubMed ID: 34975911
[TBL] [Abstract][Full Text] [Related]
7. Hypophysitis: A rare but noteworthy immune-related adverse event secondary to camrelizumab therapy.
Han X; Meng M; Zhang T; Wang J; Huang G; Ni Y; Li W; Dai J; Yang X; Ye X
J Cancer Res Ther; 2022 Sep; 18(5):1440-1443. PubMed ID: 36204895
[TBL] [Abstract][Full Text] [Related]
8. A Fatal Case of Myocarditis Following Myositis Induced by Pembrolizumab Treatment for Metastatic Upper Urinary Tract Urothelial Carcinoma.
Matsui H; Kawai T; Sato Y; Ishida J; Kadowaki H; Akiyama Y; Yamada Y; Nakamura M; Yamada D; Akazawa H; Suzuki M; Komuro I; Kume H
Int Heart J; 2020 Sep; 61(5):1070-1074. PubMed ID: 32921673
[TBL] [Abstract][Full Text] [Related]
9. Immune checkpoint inhibitor-induced myocarditis in lung cancer patients: a case report of sintilimab-induced myocarditis and a review of the literature.
Bi H; Ren D; Wang Q; Ding X; Wang H
Ann Palliat Med; 2021 Jan; 10(1):793-802. PubMed ID: 33545801
[TBL] [Abstract][Full Text] [Related]
10. Camrelizumab-Related Myocarditis and Myositis With Myasthenia Gravis: A Case Report and Literature Review.
Bai J; Li D; Yang P; Xu K; Wang Y; Li Q; Liu J; Du W; Zhang F; Feng R
Front Oncol; 2021; 11():778185. PubMed ID: 35047395
[TBL] [Abstract][Full Text] [Related]
11. Fatal Myocarditis Following Treatment with the PD-1 Inhibitor Nivolumab.
Matson DR; Accola MA; Rehrauer WM; Corliss RF
J Forensic Sci; 2018 May; 63(3):954-957. PubMed ID: 28833116
[TBL] [Abstract][Full Text] [Related]
12. Heart-Specific Immune Responses in an Animal Model of Autoimmune-Related Myocarditis Mitigated by an Immunoproteasome Inhibitor and Genetic Ablation.
Bockstahler M; Fischer A; Goetzke CC; Neumaier HL; Sauter M; Kespohl M; Müller AM; Meckes C; Salbach C; Schenk M; Heuser A; Landmesser U; Weiner J; Meder B; Lehmann L; Kratzer A; Klingel K; Katus HA; Kaya Z; Beling A
Circulation; 2020 Jun; 141(23):1885-1902. PubMed ID: 32160764
[TBL] [Abstract][Full Text] [Related]
13. Immunomodulatory treatment of immune checkpoint inhibitor-induced myocarditis: Pathway toward precision-based therapy.
Balanescu DV; Donisan T; Palaskas N; Lopez-Mattei J; Kim PY; Buja LM; McNamara DM; Kobashigawa JA; Durand JB; Iliescu CA
Cardiovasc Pathol; 2020; 47():107211. PubMed ID: 32268262
[TBL] [Abstract][Full Text] [Related]
14. [Clinical and histopathological features of immune checkpoint inhibitor-related myositis in patients with advanced non-small cell lung cancer].
Jiang JJ; Li YQ; Gu YY
Zhonghua Jie He He Hu Xi Za Zhi; 2022 Jan; 45(1):47-52. PubMed ID: 35000305
[No Abstract] [Full Text] [Related]
15. Complete Atrioventricular Block Associated with Pembrolizumab-induced Acute Myocarditis: The Need for Close Cardiac Monitoring.
Katsume Y; Isawa T; Toi Y; Fukuda R; Kondo Y; Sugawara S; Ootomo T
Intern Med; 2018 Nov; 57(21):3157-3162. PubMed ID: 29877257
[TBL] [Abstract][Full Text] [Related]
16. Unanticipated Myocarditis in a Surgical Patient Treated With Pembrolizumab: A Case Report.
Nierstedt RT; Yeahia R; Barnett KM
A A Pract; 2020 Apr; 14(6):e01177. PubMed ID: 32132361
[TBL] [Abstract][Full Text] [Related]
17. Incidence and Distinct Features of Immune Checkpoint Inhibitor-Related Myositis From Idiopathic Inflammatory Myositis: A Single-Center Experience With Systematic Literature Review and Meta-Analysis.
Hamada N; Maeda A; Takase-Minegishi K; Kirino Y; Sugiyama Y; Namkoong H; Horita N; Yoshimi R; Nakajima H;
Front Immunol; 2021; 12():803410. PubMed ID: 34938300
[TBL] [Abstract][Full Text] [Related]
18. PD-1 inhibitors-associated myocarditis in non-small cell lung cancer patients.
He Y; Chen W; Cai J; Luo C; Zhou C; Wei L
J Thorac Dis; 2023 Sep; 15(9):4606-4619. PubMed ID: 37868865
[TBL] [Abstract][Full Text] [Related]
19. Plasma exchange plus glucocorticoids in the treatment of immune checkpoint inhibitor-induced myocarditis: A case series and review.
Ke G; Chen P; Luo J; Huang J; Shang Y; Huang Y; Fu N; Peng H; Li Y; Wang B; Guan W; Peng Y; Yu X; Xiao J
Clin Cardiol; 2023 Dec; 46(12):1481-1487. PubMed ID: 37698123
[TBL] [Abstract][Full Text] [Related]
20. Re-introducing immunotherapy in patients surviving immune checkpoint inhibitors-mediated myocarditis.
Peleg Hasson S; Salwen B; Sivan A; Shamai S; Geva R; Merimsky O; Raphael A; Shmilovich H; Moshkovits Y; Kapusta L; Rozenbaum Z; Wolf I; Laufer-Perl M
Clin Res Cardiol; 2021 Jan; 110(1):50-60. PubMed ID: 32296970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
